| Thomas Seidel, | |
|
351 S Washburn St, Oshkosh, WI 54904-7932 | |
| (920) 231-2219 | |
| Not Available |
| Full Name | Thomas Seidel |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 351 S Washburn St, Oshkosh, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033717426 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 18666-40 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Seidel, 351 S Washburn St, Oshkosh, WI 54904-7932 Ph: () - | Thomas Seidel, 351 S Washburn St, Oshkosh, WI 54904-7932 Ph: (920) 231-2219 |
News Archive
Adolescents who have half-siblings with a different father are more likely to have used drugs and had sex by age 15 than those who have only full siblings. That's according to new research from Karen Benjamin Guzzo, an assistant professor of sociology at Bowling Green State University, and Cassandra Dorius, an assistant professor of human development and family studies at Iowa State University.
The digital rectal exam is an important screening test that can discover prostate cancer that a prostate-specific antigen or PSA test may not, despite the higher sensitivity of the PSA test, according to Penn State College of Medicine researchers.
The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.
In more and more hospitals across the U.S., patients turn to palliative care specialists to provide relief from pain, help in making difficult medical decisions and support for their families and those who care for them.
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
› Verified 8 days ago
Dr. Vaibhav Kadakia, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 351 S Washburn St, Oshkosh, WI 54904 Phone: 920-231-2219 | |
Derek Kolaga, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 351 S Washburn St, Oshkosh, WI 54904 Phone: 920-231-2219 | |
Dr. Tarek H Elawa, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 950 S Koeller St, Oshkosh, WI 54902 Phone: 920-303-1712 | |
Dr. Tyler Nickel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 Emmers Ln, Oshkosh, WI 54904 Phone: 920-237-4753 Fax: 920-237-4756 | |
Mr. Charles J O'hagan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1465 Maricopa Dr, Oshkosh, WI 54904 Phone: 847-302-3195 | |
Cindy Krummick, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1940 S Koeller St, Oshkosh, WI 54902 Phone: 920-236-9494 Fax: 920-236-8876 |